Cytomegalovirus-specific cellular immune responses and viremia in recipients of allogeneic stem cell transplants

被引:106
作者
Aubert, G
Hassan-Walker, AF
Madrigal, JA
Emery, VC
Morte, C
Grace, S
Koh, MBC
Potter, M
Prentice, HG
Dodi, IA
Travers, PJ
机构
[1] UCL Royal Free & Univ Coll Med Sch, Dept Haematol, Anthony Nolan Res Inst, London NW3 2QG, England
[2] UCL Royal Free & Univ Coll Med Sch, Dept Virol, London NW3 2QG, England
[3] UCL Royal Free & Univ Coll Med Sch, Dept Haematol, London NW3 2QG, England
关键词
D O I
10.1086/323354
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The immune suppression inherent in allogeneic stem cell transplantation (SCT) offers a favorable environment for infection by opportunistic agents, such as human cytomegalovirus (CMV). Despite the application of potent antiviral prophylaxis, patients remain at risk for CMV infection until adequate immunity is restored. CMV-specific CD8(+) T cell counts were monitored, using HLA-A2 tetrameric complexes, to establish the level of immune response to the viral phosphoprotein UL83 in patients after allogeneic SCT. Correlating this with viral replication and clinical status shows that the level of tetramer-positive T cells provides an assessment of CMV immune reconstitution after stem cell transplantation. Most patients with seropositive donors did reconstitute long-term CMV immunity, unless prolonged immunosuppression to control graft-versus-host disease was induced. Together with polymerase chain reaction testing, this technique provides measurable parameters that can be a guide to therapeutic decision making and can form the basis of CMV immunotherapy.
引用
收藏
页码:955 / 963
页数:9
相关论文
共 36 条
[1]  
Altman JD, 1998, SCIENCE, V280, P1821
[2]   FOSCARNET FOR TREATMENT OF CYTOMEGALOVIRUS INFECTIONS IN BONE-MARROW TRANSPLANT RECIPIENTS [J].
ASCHAN, J ;
RINGDEN, O ;
LJUNGMAN, P ;
LONNQVIST, B ;
OHLMAN, S .
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 1992, 24 (02) :143-150
[3]  
Bacigalupo A, 1996, BONE MARROW TRANSPL, V18, P110
[4]  
Couriel D, 1996, BONE MARROW TRANSPL, V18, P347
[5]   Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection [J].
Diamond, DJ ;
York, J ;
Sun, JY ;
Wright, CL ;
Forman, SJ .
BLOOD, 1997, 90 (05) :1751-1767
[6]  
EINSELE H, 1995, BLOOD, V86, P2815
[7]   Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy [J].
Emery, VC ;
Griffiths, PD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (14) :8039-8044
[8]   Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation [J].
Emery, VC ;
Sabin, CA ;
Cope, AV ;
Gor, D ;
Hassan-Walker, AF ;
Griffiths, PD .
LANCET, 2000, 355 (9220) :2032-2036
[9]   Functional heterogeneity and high frequencies of cytomegalovirus-specific CD8+ T lymphocytes in healthy seropositive donors [J].
Gillespie, GMA ;
Wills, MR ;
Appay, V ;
O'Callaghan, C ;
Murphy, M ;
Smith, N ;
Sissons, P ;
Rowland-Jones, S ;
Bell, JI ;
Moss, PAH .
JOURNAL OF VIROLOGY, 2000, 74 (17) :8140-8150
[10]   EARLY TREATMENT WITH GANCICLOVIR TO PREVENT CYTOMEGALOVIRUS DISEASE AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION [J].
GOODRICH, JM ;
MORI, M ;
GLEAVES, CA ;
DUMOND, C ;
CAYS, M ;
EBELING, DF ;
BUHLES, WC ;
DEARMOND, B ;
MEYERS, JD .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (23) :1601-1607